Abzena PLC Licensed product candidate update (0586O)
02 November 2016 - 6:00PM
UK Regulatory
TIDMABZA
RNS Number : 0586O
Abzena PLC
02 November 2016
Abzena plc
Licensed product candidate update
Cambridge, UK, 2 November 2016 - Abzena plc (AIM: ABZA,
'Abzena'), a life sciences group providing services and
technologies enabling the development and manufacture of
biopharmaceutical products, notes that during the conference call
to accompany Gilead Sciences Inc.'s ('Gilead') announcement of
third quarter earnings on 1 November 2016, Gilead stated that no
further development of simtuzumab will be pursued. In addition,
GS-5745 will not be progressed further for Crohns Disease.
This follows on from the announcement on 20 October 2016 of top
line Phase II clinical study results of Gilead's product, GS-4997
(selonsertib) in combination with the investigational monoclonal
antibody, simtuzumab (SIM) or SIM alone, in patients with
non-alcoholic steatohepatitis (NASH).
Simtuzumab and GS-5745 are part of a range of products created
using Abzena's Composite Human Antibody(TM) technology that its
partners have been progressing in clinical development.
Further information about Abzena's portfolio of Composite Human
Antibodies(TM) - 'Abzena Inside' products - in clinical
development, and the range of Abzena's services and technologies,
can be found on the website: www.abzena.com.
The announcement and presentation for Gilead's third quarter
earnings can be found here:
http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-earnings
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer
Julian Smith, Chief Financial
Officer +44 1223 903498
Numis (Nominated Adviser and
Broker) +44 20 7260
Clare Terlouw / Paul Gillam 1000
N+1 Singer (Joint Broker) +44 20 7496
Aubrey Powell / Liz Yong 3000
Instinctif Partners +44 20 7457 2020
Melanie-Toyne Sewell / Rozi abzena@instinctif.com
Morris
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products, a growing area that requires specialist
knowledge and expertise. The Group has a global customer base which
includes the majority of the top 20 biopharmaceutical companies as
well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA).
-- Immunogenicity assessment, protein engineering to create
humanized antibodies and deimmunised therapeutic proteins, and cell
line development for manufacture.
-- Contract process development and manufacture of
biopharmaceuticals, including monoclonal antibodies, recombinant
proteins, vaccines, and gene therapy and cell therapy products, for
preclinical and clinical studies.
-- Proprietary site-specific conjugation technologies for
antibody drug conjugate development and solutions for optimizing
the therapeutic properties of biopharmaceuticals.
-- Contract chemistry and bioconjugation business focused on
ADCs and is establishing the capability to manufacture ADCs to GMP
standards.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFSDSSEFMSESF
(END) Dow Jones Newswires
November 02, 2016 03:00 ET (07:00 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024